MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
India's Third Giant Leap
This Leap Could Potentially Generate Gains
Far Bigger than Anything We Have Seen in Our Lifetimes
- Home
- Stock Quote (indian pharma)
- SUN PHARMA
SUN PHARMA Share Price 
(SUNP)
Here is the latest stock price and chart of SUN PHARMA. For more details, see the SUN PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report. Since large caps interest you, here's our guide to buying bluechip stocks.
| Live BSE Quotes | Feb 1, 2023 (Close) | ||
|---|---|---|---|
| Price (Rs)1,014.15 | Open (Rs) 1,032.15 | High (Rs) 1,042.30 | Low (Rs) 1,005.30 |
| % Change-2.01 | Volume 155,897 | Value (Rs) 158,037,370 | 52-Week H/L 1,071.90 / 789.75 |
| Live NSE Quotes | Feb 1, 2023 (Close) | ||
|---|---|---|---|
| Price (Rs)1,014.90 | Open (Rs) 1,036.45 | High (Rs) 1,043.95 | Low (Rs) 1,005.10 |
| % Change-1.89 | Volume 4,717,887 | Value (Rs) 4,781,808,031 | 52-Week H/L 1,072.15 / 789.90 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -2.01% | 1 Month 1.71% | 3 Months -1.83% | 1 Year 13.69% | 5 Years (CAGR)* 12.76% | 10 Years (CAGR)* 10.92% |
* Compound Annual Growth Rate
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 18.01 | P/E Ratio (x) 56.30 | Market Cap (Rs m) 2,433,285.59 | P/BV (x) 4.68 | Dividend Yield (%) 0.99 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
SUN PHARMA Share Price Today:
SUN PHARMA last traded price was down 2.0% to Rs 1,014.2 on the BSE. On the NSE, SUN PHARMA last traded price was down 1.9% to Rs 1,014.9. The total volume of shares traded was 4.9 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.3%. And the benchmark S&P BSE SENSEX was at 59,708.1 (up 0.3%).
Over the last 30 days, the SUN PHARMA share price is up 1.7%. And over the last one year, SUN PHARMA share price is up 21.6%.
The current market capitalisation of SUN PHARMA stands at Rs 2,433,285.59 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of December 2022, promoter pledging in SUN PHARMA stands at 1.92%. To know more, check out the latest shareholding pattern of SUN PHARMA.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
FAQs on SUN PHARMA
What is the SUN PHARMA share price today?
The last traded price of SUN PHARMA was Rs 1,014.2 on the BSE, down 2.0% over the previous close. On the NSE, SUN PHARMA last traded price was down 1.9% at Rs 1,014.9.
What is the market cap of SUN PHARMA?
The current market capitalisation of SUN PHARMA stands at Rs 2,433,286 m. For more information, check out the list of top 100 companies in India in terms of market cap.
What is the Earnings per share (EPS) of SUN PHARMA?
SUN PHARMA had an EPS of Rs 18.0 in the latest financial year. In the most recent quarter, the company declared an EPS of Rs 9.1.
What is the PE Ratio and PB Ratio of SUN PHARMA?
What is the Dividend Yield of SUN PHARMA?
For the financial year 2022, SUN PHARMA declared dividend amounting to Rs 10.0 per share. At the current price of Rs 1,014.2, this results in a dividend yield of 1.0%.
Today's Market
Adani Group's Port Acquisition | Why Defence Stocks are Falling | Top Buzzing Stocks Today(Pre-Open)
On Wednesday, Indian share markets witnessed high volatility as Adani group stocks and insurance companies fell sharply in the second half, dampening overall sentiment.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.